Compare Bristol-Myers Squibb Co (BMY) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Bristol-Myers Squibb Co trades at $63.84 (market cap $129.94B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.28. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while YieldMax Magnificent 7 Fund of Option Income ETFs pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| BMY | YMAG | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $65.89 | $15.98 |
52-Week Low | $42.60 | $10.76 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
YMAG trades at $11.33, down 2.24% today, with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, with recent payments ranging from $0.07 to $0.40 per share. Technical indicators show strong trend momentum with ADX readings above 25, while RSI suggests potential overbought conditions on shorter timeframes.
YMAG's option income strategy generates substantial distributions but faces NAV stability challenges during earnings periods. The fund's structure effectively monetizes volatility in rangebound markets, though concentrated exposure to Magnificent Seven stocks creates single-sector risk. Current price action tests key support at $11-$12 resistance levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
